The siRNN technology that Solstice licensed from UCSD could take RNAi-based therapies to tissues outside the liver and expand their use to a host of new diseases.
Moving discoveries from academia to industry requires a delicate balance of risk, reward, skill sets and personalities, according to a translational panel held at BIO-Europe's partnering conference.
Yabao and MRC Technology partner in PD; charities form Neuro-MAP to insource pharma's abandoned compounds; Singapore creates a diagnostic hub; a roundup of public-private partnerships.
TARGETS & MECHANISMS
Heidelberg Pharma has resuscitated a long-dead ADC toxin with updated conjugation techniques, and its partner Roche has thrown the company a lifeline that could help validate the platform.
Genocea has identified an immunological imprint in patients with malaria and is using a $1.2 million grant from the Gates Foundation to turn the findings into a vaccine.
Using chemically modified carbohydrates as cancer vaccine antigens; preventing doxorubicin-induced cardiotoxicity with ophiopogonin D; inhibiting VEGF receptor to treat tuberculosis; and more...
High throughput, miniaturized chemical synthesis for lead compound discovery; antimiR-peptide conjugates that cross cell membranes; a four-gene panel for diagnosing eosinophilic esophagitis; and more...